Table 3.
Association between CYB5R1 expression and clinicopathological features in patients with gastric cancer.
| Overall | High CYB5R1 | Low CYB5R1 | p value | |
|---|---|---|---|---|
| Variable | 348 | 174 | 174 | |
| Gender (%) | 0.116 | |||
| female | 123(35.3) | 54(31.0) | 69(39.7) | |
| male | 225(64.7) | 120(69.0) | 105(60.3) | |
| Race (%) | 0.595 | |||
| asian | 72 (20.7) | 32 (18.4) | 40 (23.0) | |
| black | 10 (2.9) | 5 (2.9) | 5 (2.9) | |
| not reported | 46 (13.2) | 21 (12.1) | 25 (14.4) | |
| white | 220 (63.2) | 116 (66.7) | 104 (59.8) | |
| Age (%) | 0.001* | |||
| <60 | 157(45.5) | 95(54.9) | 62(36.0) | |
| ≥60 | 188(54.5) | 78(45.1) | 110(64.0) | |
| T_stage (%) | 0.078 | |||
| T1 | 19 (5.5) | 15 (8.6) | 4 (2.3) | |
| T2 | 75 (21.6) | 41 (23.6) | 34 (19.5) | |
| T3 | 157 (45.1) | 74 (42.5) | 83 (47.7) | |
| T4 | 93 (26.7) | 42 (24.1) | 51 (29.3) | |
| TX | 4 (1.1) | 2 (1.1) | 2 (1.1) | |
| N_stage (%) | 0.579 | |||
| N0 | 104 (29.9) | 56 (32.2) | 48 (27.6) | |
| N1 | 92 (26.4) | 46 (26.4) | 46 (26.4) | |
| N2 | 71 (20.4) | 35 (20.1) | 36 (20.7) | |
| N3 | 70 (20.1) | 30 (17.2) | 40 (23.0) | |
| Nx | 11 (3.2) | 7 (4.0) | 4 (2.3) | |
| M_stage (%) | 0.87 | |||
| M0 | 311 (89.4) | 157 (90.2) | 154 (88.5) | |
| M1 | 22 (6.3) | 10 (5.7) | 12 (6.9) | |
| MX | 15 (4.3) | 7 (4.0) | 8 (4.6) | |
| Stage (%) | 0.019* | |||
| Stage I | 50 (14.4) | 36 (20.7) | 14 (8.0) | |
| Stage II | 107 (30.7) | 50 (28.7) | 57 (32.8) | |
| Stage III | 143 (41.1) | 67 (38.5) | 76 (43.7) | |
| Stage IV | 34 (9.8) | 14 (8.0) | 20 (11.5) | |
| not reported | 14 (4.0) | 7 (4.0) | 7 (4.0) | |
| Primary_tumor_location (%) | 0.019* | |||
| Body of stomach | 85 (24.4) | 37 (21.3) | 48 (27.6) | |
| Cardia, NOS | 84 (24.1) | 54 (31.0) | 30 (17.2) | |
| Fundus of stomach | 40 (11.5) | 23 (13.2) | 17 (9.8) | |
| Gastric antrum | 127 (36.5) | 55 (31.6) | 72 (41.4) | |
| not reported | 12 (3.4) | 5 (2.9) | 7 (4.0) | |
|
Stemness score (median [IQR]) |
0.41 [0.33, 0.48] | 0.41 [0.30, 0.45] | 0.44 [0.36, 0.52] | <0.001* |
⁎
p-value < 0.05.